Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody

BACKGROUND: Success of T cell immunotherapy hinges on the tumor microenvironment (TME), and abnormal tumor vasculature is a hallmark of most solid tumors and associated with immune evasion. The efficacy of T cell engaging bispecific antibody (BsAb) treatment relies on the successful trafficking and...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jeong A, Espinosa-Cotton, Madelyn, Guo, Hong-fen, Monette, Sebastien, Cheung, Nai-Kong V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069597/
https://www.ncbi.nlm.nih.gov/pubmed/36990507
http://dx.doi.org/10.1136/jitc-2023-006680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069597/
https://www.ncbi.nlm.nih.gov/pubmed/36990507
http://dx.doi.org/10.1136/jitc-2023-006680

Ejemplares similares